

How can we reduce the preterm delivery rate?

Bo Jacobsson

**Professor, MD, PhD,
Department of Obstetrics and Gynecology
Sahlgrenska University Hospital,
Gothenburg, Sweden**

**Senior researcher,
Norwegian Institute of Public Health
Oslo, Norway**



Congrés Català
**d'Obstetrícia
i Ginecologia**

7, 8, 9 novembre de 2018
Auditori AXA, Barcelona


CONFLICTS OF INTEREST

Performed NIPT clinical diagnostic trails for Ariosa, Natera and Vanadis –
NO personal reimbursements, no talks or promotional actives for the companies

Performed an intra-amniotic infection clinical diagnostic trail for Hologic –
NO personal reimbursements, no talks or other promotional activities for the
company

Pregnancy


Preterm delivery rate




Little progress

Neonatal period

Neonatal mortality




Huge progress




**Due to lack of basic understanding of pregnancy and delivery
Major research effort to understand this pregnancy issues**

A huge international effort on women's health




Research and constant simultaneous registration and validation



Mandatory registers – continuous validation of data and interventions



Burden of mortality and impairment for 15 million preterm babies born in 2010



Blencowe H et al 2013 *Pediatric Research* 74:


Shift some of the focus from only early to some of the late

OVERVIEW OF THE TALK

1. PRETERM DELIVERY RATES? SO WHERE IS THE BOTTOM LINE? BIOLOGICAL VARIATIONS?
2. REFLEXION ON PHENOTYPE – WHAT CAN BE EXPECTED?
3. CALCULATION EXEMPLES FROM CURRENT KNOWLEDGE?
4. WHICH STRATGIES WILL BE NEEDED? STRATEGIES ON MANY DIFFERENT FRONTS.

Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index

Hannah H Chang, Jim Larson, Hannah Blencowe, Catherine Y Spong, Christopher P Howson, Sarah Cairns-Smith, Eve M Lackritz, Shoo K Lee, Elizabeth Mason, Andrew C Serazin, Salimah Walani, Joe Leigh Simpson, Joy E Lawn, on behalf of the Born Too Soon preterm prevention analysis group



HUGE VARIATION OF PRETERM DELIVERY RATES IN HIGH INCOME COUNTRIES

CYPRES 14.7%
GERMANY 9.2%

.....
FINLAND 5.5%
CROATIA 5.5%
LATVIA 5.3%

Original investigation

The Distribution of Clinical Phenotypes of Preterm Birth Syndrome Implication for Prevention

Intergrowth – 21st Project

Low risk population PRETERM BIRTH RATE 4.5%

Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index

Hannah H Chang, Jim Larson, Hannah Blencowe, Catherine Y Spong, Christopher P Howson, Sarah Cairns-Smith, Eve M Lackritz, Shook K Lee, Elizabeth Mason, Andrew C Serazin, Salimah Walani, Joe Leigh Simpson, Joy E Lawn, on behalf of the Born Too Soon preterm prevention analysis group



I think we can agree on these huge differences are most likely not due to biology!



9.2%



Germany

Corrected



8.4%



Germany



-2.5%

5.9%



Sweden

If we better can understand this 2.5% difference we can do a lot

OVERVIEW OF THE TALK


1. PRETERM DELIVERY RATES? SO WHERE IS THE BOTTOM LINE? BIOLOGICAL VARIATIONS?

2. REFLEXION ON PHENOTYPE – WHAT CAN BE EXPECTED?

3. CALCULATION EXEMPLES FROM CURRENT KNOWLEDGE?


4. WHICH STRATGIES WILL BE NEEDED? STRATEGIES ON MANY DIFFERENT FRONTS.

Preterm delivery




Preterm delivery


Gestational age




Preterm delivery – syndrome of syndromes



Mortality < 70 years




Preterm delivery – syndrome of syndromes



Preterm labor

Gestational age


37 weeks




PTL



Preterm labor



CONCLUSION: NO EASY UNDERSTANDING OF A PHENOTYPE LIKE THIS – SYNDROME OF SYNDROMES



THE FINAL BREAKTHROUGH

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

Genetic Associations with Gestational Duration and Spontaneous Preterm Birth


G. Zhang, B. Feenstra, J. Bacelis, X. Liu, L.M. Muglia, J. Juodakis, D.E. Miller, N. Litterman, P.-P. Jiang, L. Russell, D.A. Hinds, Y. Hu, M.T. Weirauch, X. Chen, A.R. Chavan, G.P. Wagner, M. Pavličev, M.C. Nnamani, J. Maziarz, M.K. Karjalainen, M. Rämetsä, V. Sengpiel, F. Geller, H.A. Boyd, A. Palotie, A. Momany, B. Bedell, K.K. Ryckman, J.M. Huusko, C.R. Forney, L.C. Kottyan, M. Hallman, K. Teramo, E.A. Nohr, G. Davey Smith, M. Melbye, B. Jacobsson, and L.J. Muglia

Drs. Jacobsson and Muglia contributed equally to this article.

Gestational Duration



Preterm Birth



N Engl. 1156-67

DOI: 10.1056/NEJMoal1612665

Genotypes of 44,000 women in collaboration with 23andMe, Inc.

OVERVIEW OF THE TALK




1. PRETERM DELIVERY RATES? SO WHERE IS THE BOTTOM LINE? BIOLOGICAL VARIATIONS?

2. REFLEXION ON PHENOTYPE – WHAT CAN BE EXPECTED?



3. CALCULATION EXEMPLES FROM CURRENT KNOWLEDGE?

4. WHICH STRATGIES WILL BE NEEDED? STRATEGIES ON MANY DIFFERENT FRONTS.



Progesteron



Cervical cerclage



Cervical pessary



OR around 0.6 but how much do that mean in real figures on the preterm delivery rate?

The effect of the treatment

X

The fraction of the overall phenotype related to the
specific indications for the treatment

=

Reduction of the overall phenotype rate

Population Attributable Fraction

Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index

Hannah H Chang, Jim Larson, Hannah Blencowe, Catherine Y Spong, Christopher P Howson, Sarah Cairns-Smith, Eve M Lackritz, Shoo K Lee, Elizabeth Mason, Andrew C Serazin, Salimah Walani, Joe Leigh Simpson, Jay E Lawn, on behalf of the Born Too Soon preterm prevention analysis group






Figure 6: Projected change from 2010 baseline preterm birth rate showing modelled contribution of the five selected interventions



Many doctors want action




Many patients want action



Many doctors want to do things

We need to produce and follow guidelines



Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index

Hannah H Chang, Jim Larson, Hannah Blencowe, Catherine Y Spong, Christopher P Howson, Sarah Cairns-Smith, Eve M Lackritz, Shoo K Lee, Elizabeth Mason, Andrew C Serazin, Salimah Walani, Joe Leigh Simpson, Jay E Lawn, on behalf of the Born Too Soon preterm prevention analysis group





Figure 6: Projected change from 2010 baseline preterm birth rate showing modelled contribution of the five selected interventions




**What is the best outcome of
the fertility treatment?**

One healthy baby


**Multiple pregnancy is a problem
both from ovarian stimulation
and from multiple embryo transfer**



\geq Week 37 or \geq 39




ART



Gestational age and
multiple pregnancy
matters

First: do no harm



Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index

Hannah H Chang, Jim Larson, Hannah Blencowe, Catherine Y Spong, Christopher P Howson, Sarah Cairns-Smith, Eve M Lackritz, Shoo K Lee, Elizabeth Mason, Andrew C Serazin, Salimah Walani, Joe Leigh Simpson, Jay E Lawn, on behalf of the Born Too Soon preterm prevention analysis group




Figure 6: Projected change from 2010 baseline preterm birth rate showing modelled contribution of the five selected interventions

Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index

Hannah H Chang, Jim Larson, Hannah Blencowe, Catherine Y Spong, Christopher P Howson, Sarah Cairns-Smith, Eve M Lackritz, Shoo K Lee, Elizabeth Mason, Andrew C Serazin, Salimah Walani, Joe Leigh Simpson, Jay E Lawn, on behalf of the Born Too Soon preterm prevention analysis group




Figure 6: Projected change from 2010 baseline preterm birth rate showing modelled contribution of the five selected interventions

Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index

Hannah H Chang, Jim Larson, Hannah Blencowe, Catherine Y Spong, Christopher P Howson, Sarah Cairns-Smith, Eve M Lackritz, Shoo K Lee, Elizabeth Mason, Andrew C Serazin, Salimah Walani, Joe Leigh Simpson, Jay E Lawn, on behalf of the Born Too Soon preterm prevention analysis group




Figure 6: Projected change from 2010 baseline preterm birth rate showing modelled contribution of the five selected interventions

Cost-effectiveness of risk-based screening for cervical length to prevent preterm birth

Brett D. Einerson, MD, MPH; William A. Grobman, MD, MBA; Emily S. Miller, MD, MPH

American Journal of Obstetrics & Gynecology 2016;215:100.e1-7.

Prevalence of short cervix $\leq 20\text{mm}$ 0.85%

Relative risk reduction of delivery < 35 weeks RR 0.6

2.2 million scans required

11 000 need treatment

About 900 PTD < 35 weeks will be prevented

A reduction from 9.57% to 9.55% in PTD rates

HUGE EFFORTS
SMALL OVERALL EFFECT

OVERVIEW OF THE TALK

1. PRETERM DELIVERY RATES? SO WHERE IS THE BOTTOM LINE? BIOLOGICAL VARIATIONS?

2. REFLEXION ON PHENOTYPE – WHAT CAN BE EXPECTED?


3. CALCULATION EXEMPLES FROM CURRENT KNOWLEDGE?

4. WHICH STRATGIES WILL BE NEEDED? STRATEGIES ON MANY DIFFERENT FRONTS.

COMPLEX PHENOTYPE IS NOT A DEAD END

ANOTHER COMPLEX PHENOTYPE
IS TRAFIC FATALITIES
WITH A SUCCESSFUL REDUCTION

TRAFIC FATALITIES IN SWEDEN 1950-2010




● Number of deaths

● Traffic volume

TRAFIC FATALITIES REDUCTION STRATEGY

Accidents



OVERVIEW OF THE TALK

5. RESEARCH IS NEEDED. WHICH RESEARCH TO PRIORITIZE?

6. QUALITATIVE CONTINUOUS FOLLOW UP

7. PROFESIONAL GUIDELINES AND GOVERNMENT ROLES

Cross-Country Individual Participant Analysis of 4.1 Million Singleton Births in 5 Countries with Very High Human Development Index Confirms Known Associations but Provides No Biologic Explanation for 2/3 of All Preterm Births

David M. Ferrero¹, Jim Larson¹, Bo Jacobsson^{4,13}, Gian Carlo Di Renzo^{3,10}, Jane E. Norman⁸, James N. Martin, Jr.⁶, Mary D'Alton⁷, Ernesto Castelazo³, Chris P. Howson², Verena Sengpiel⁴, Matteo Bottai⁹, Jonathan A. Mayo⁵, Gary M. Shaw⁵, Ivan Verdenik¹¹, Nataša Tul¹¹, Petr Velebil¹², Sarah Cairns-Smith¹, Hamid Rushwan³, Sabaratnam Arulkumaran³, Jennifer L. Howse², Joe Leigh Simpson^{2*}

Patient-level pregnancy and birth data


Czech Republic
(n=1.3M)

New Zealand
(n=247K)

Slovenia
(n=175K)

Sweden
(n=1.1M)

California
(comparator state,
n=1.3M)




18 prioritized risk factors


Patient-level data



Risk factor prevalence




Patient-level data




Odds ratios for each risk factor

Odds ratios for each risk factor



Prevalence of risk factors (range of sources)

What is known?




How much can these public health data explain differences in preterm birth rates in high income countries?




	Countries				Comparator US state
	Czech Rep.	New Zealand	Slovenia	Sweden	California
Previous PTB	5.2**	5.7**	4.6**	6.0**	5.0**
Preeclampsia	4.8**	3.4**	2.8**	5.7**	4.2**
Diabetes (chronic)	3.4**		1.9**	3.6**	
Hypertension (chronic)			2.1**	1.7**	3.0**
Maternal Age					
Age > 40	1.8**	1.3**	1.6**	1.4**	1.5**
Age 35-40	1.4**	1.2**	1.4**	1.2**	1.3**
Age < 20	1.1**	1.1	1.1	0.9*	1.0
Nulliparous	1.5**	1.4**	1.6**	2.1**	1.2**
ART			1.7**	1.3**	1.7**
Drug use (illicit)	1.7**				
Ethnicity					
Ethnicity (other)					1.7**
Ethnicity (Non-Hispanic Black)					1.6**
Ethnicity (Asian)		1.0			1.3**
Ethnicity (Hispanic)					1.2**
Ethnicity (Pacific P)		0.9**			
Ethnicity (MELAA)		1.1			
Ethnicity (Maori)		1.0			
Smoking	1.3**	1.6**	1.3**	1.3**	1.4**
Diabetes (gestational)	1.3**	1.9**	1.3*	0.9*	1.3**
Hypertension (gestational)	1.3**		1.6**	0.6**	
BMI					
BMI (underweight)			1.4**	1.3**	1.3**
BMI (overweight)			0.9	1.0**	1.0
BMI (obese – class I)			0.9	1.1**	1.0**
BMI (obese – class II & III)			0.8	1.3**	1.1**


Slovenia




Sweden




Slovenia



Sweden



AREAS OF INTERVENTION



OVERVIEW OF THE TALK

5. RESEARCH IS NEEDED. WHICH RESEARCH TO PRIORITIZE?

6. CONTINUOUS QUALITATIVE FOLLOW UP

7. PROFESSIONAL GUIDELINES AND GOVERNMENT ROLES

Mandatory registers – continuous validation of data and interventions



OVERVIEW OF THE TALK


5. WHAT TO DO WITH CURRENT KNOWLEDGE? LOW HANGING FRUITS.

6. RESEARCH IS NEEDED. WHICH RESEARCH TO PRIORITIZE?

7. QUALITATIVE CONTINUOUS FOLLOW UP

8. PROFESSIONAL GUIDELINES AND GOVERNMENTAL ROLES


Professional organizations issues guidelines + engage in society building




Medical tourism




We also need to look at health care organization/government issues




Research and constant simultaneous validation




Research and constant simultaneous registration and validation




Research and constant simultaneous registration and validation




Research and constant simultaneous registration and validation




Research and constant simultaneous registration and validation




Research and constant simultaneous registration and validation




Research and constant simultaneous registration and validation




Research and constant simultaneous registration and validation



Research and constant simultaneous registration and validation



Research and constant simultaneous registration and validation



A joint huge effort on women's health

**Government -
Funding
organizations**



**Parents
organizations:
EFCINI**

Industry

**Professional
organizations:
FIGO et al**



Thanks



Thanks

**Especially to Dr
Teresa Cobo**

